Can amiodarone prevent sudden cardiac death in patients with hemodynamically tolerated sustained ventricular tachycardia and coronary artery disease?

Cardiovascular Drugs and Therapy

Volumn 19, Issue 3, 2005, Pages 219-226

  Arya, Arash ^a   Haghjoo, Majid ^a   Sadr Ameli, Mohammad Ali ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amiodarone; Coronary artery disease; Implantable defibrillators; Secondary prevention; Sudden cardiac death; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY HEMODYNAMICS; DEFIBRILLATOR; DRUG EFFICACY; DRUG INDICATION; HEART ARREST; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

AMIODARONE; CLINICAL TRIALS; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; TACHYCARDIA, VENTRICULAR;

EID: 24344483554     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-2502-8     Document Type: Review

References (68)

1. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal 2001;22:1374-1450.
2. Connolly SJ. Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation 1999;100:2025-2034.
3. Ezekowitz JA, Armstrong PW, McAlister A. Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials. Ann Intern Med 2003;138:445-452.
4. Gregoratos G, Abrams J, Epstein AE, et al. American College of Cardiology/ American Heart Association Task Force on Practice Guidelines American College of Cardiology/American Heart Association/North American Society for Pacing and Electrophysiology Committee. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145-2165.
5. Stevenson WG, Brugada P, Waldecker B, Zehender M, Wellens HJ. Clinical, angiographic, and electrophysiologic findings in patients with aborted sudden cardiac death as compared with patients with susyained ventricular tachycardia after myocardial infarction. Circulation 1985;71:1146-1152.
6. Khairy P, Thibault B, Talajic M, et al. Prognostic significance of ventricular arrhythmia post-myocardial infarction. Can J Cardiol 2003;19:1393-1404.
7. Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy incidence and outcomes. Circulation 1998;98:2567-2573.
8. Bigger JT Jr, Fleiss JL, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986;58:1151-1160.
9. Bodegas A, Arana J, Rumoroso JR, Rodrigo D, Barrenetxea JI. Prognosis of patients with a first episode of sustained monomorphic ventricular tachycardia. Int J Cardiol 1998;65:181-185.
10. Willems AR, Tijssen JG, van Capelle FJ, et al. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. The Dutch Ventricular Tachycardia Study Group of the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 1990;16:521-530.
11. Kleiman RB, Miller JM, Buxton AE, Josephson ME, Marchlinski FE. Prognosis following sustained ventricular tachycardia occuring early after myocardial infarction. Am J Cardiol 1988;62:528-533.
12. Al-Khatib SM, Stebbins AL, Califf RM, et al. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial. Am Heart J 2003;145:515-521.
13. Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation incidence, predictors, and outcomes. Circulation 2002;106:309-312.
14. Freedberg NA, Hill JN, Fogel RI, Prystowsky EN. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy. J Am Coll Cardiol 2001;37:1910-1915.
15. Raitt MH, Renfroe EG, Epstein AE, et al. "Stable" ventricular tachycardia is not a benign rhythm: Insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) registry. Circulation 2001;103:244-252.
16. Schläpfer J, Rapp F, Kappenberger L, Fromer M. Electro- physiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction results of long-term follow-up. J Am Coll Cardiol 2002;39:1813-1819.
17. Sarter BH, Finkle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996;28:122-129.
18. Olson PJ, Woelfel A, Simpson RJ, Foster JR. Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1993;71:823-826.
19. Stevenson WG, Friedman PL, Kocovic D, Sager PT, Saxon LA, Pavri B. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation 1998;98:308-314.
20. Bocker D, Block M, Isbruch F, et al. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J 1995;73:158-163.
21. Raitt MH, Dolack GL, Kudenchuk PJ, Poole JE, Bardy GH. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation implications for use of implantable defibrillator. Circulation 1995;91:1996-2001.
22. Caruso AC, Marcus FI, Hahn EA, Hartz VL, Mason JW. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Electrophysiologic Study Versus Electromagnetic Monitoring. Circulation 1997;96:1888-1892.
23. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-336.
24. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-258.
25. Mukharji J, Rude RE, Poole WK, et al. and the MILIS Study Group. Risk factors for sudden death after acute myocardial infarction: Two-year follow-up. Am J Cardiol 1984;54:31-36.
26. Coromilas J, Bigger JT Jr, Kleiger RE, and the MDPIT Research Group. Relations among left ventricular dysfunction, ventricular arrhythmias, and mortality after myocardial infarction. Circulation 1989;80(Suppl. II):48.
27. Yap YG, Duong T, Bland M, et al. Left ventricular ejection fraction in the thrombolytic era remains a powerful predictor of long term but not short-term all cause cardiac and arrhythmicmortality after myocardial infarction - A secondary meta-analysis of 2828 patients. J Am Coll Cardiol 2001;37(Suppl. A):445A.
28. Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 1999;34:1090-1095.
29. Domanski MJ, Epstein A, Hallstrom A, Saksena S, Zipes DP. Survival of antiarrhythmic or implantable cardioverter defibrillator treated patients with varying degrees of left ventricular dysfunction who survived malignant ventricular arrhythmias. J Cardiovasc Electrophysiol 2002;13:580-583.
30. CASCADE Investigators. Cardiac Arrest in Seattle: Conventional versus amiodarone drug evaluation. Am J Cardiol 1991;67:578-584.
31. Weinberg BA, Miles WM, Klein LS, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-120.
32. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062.
33. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991;84:550-557.
34. Hockings BE, George T, Mahrous F, Taylor RR, Hajar HA. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. Am J Cardiol 1987;60:967-970.
35. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675-682.
36. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-674.
37. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997;96:2823-2829.
38. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997;350:1417-1424.
39. Bardy GH, Lee KL, Mark DB, et al. for the Sudden Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237.
40. Waller TJ, Kay HR, Spielman SR, Kutalek SP, Greenspan AM, Horowitz LN. Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: Criteria of efficacy in patients with sustained ventricular tachyarrhythmia. J Am Coll Cardiol 1987;10:83-89.
41. Horowitz LN, Greenspan AM, Spielman SR, Frye SJ, Yacone LA, Lowenthal DT. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 1985;55:367-371.
42. Naccarelli GV, Fineberg NS, Zipes DP, Heger JJ, Duncan G, Prystowsky EN. Amiodarone: Risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 1985;6:814-821.
43. Zhu J, Haines DE, Lerman BB, DiMarco JP. Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. Circulation 1987;76:802-809.
44. Kadish AH, Buxton AE, Waxman HL, Flores B, Josephson ME, Marchlinski FE. Usefulness of electrophysiologic study to determine the clinical tolerance of arrhythmia recurrences during amiodarone therapy. J Am Coll Cardiol 1987;10:90-96.
45. Yazaki Y, Haffajee CI, Gold RL, Bishop RL, Alpert JS. Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. Am J Cardiol 1987;60:293-297.
46. Greenspon AJ, Volosin KJ, Greenberg EM, Jefferies L, Rotmensch HH. Amiodarone therapy: Role of early and late electrophysiologic studies. J Am Coll Cardiol 1988;11:117-123.
47. Mitchell LB. The role of pharmacological therapy for ventricular tachyarrhythmias: Where to go from here? In: Singer I, Barold SS, Camm AJ, eds. Nonpharmacological Therapy of Arrhythmias for the 21st Century: The State of the Art. Armonk, NY: Futura Publishing Co., 1998:565-587.
48. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter defibrillators: Incidence, management and prognostic implications. J Am Coll Cardiol 1998;32:1909-1915.
49. Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P: Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular arrhythmias. Europace 2000;2:263-269.
50. Dorian P, Mangat I. Role of Amiodarone in the Era of the Implantable Cardioverter Defibrillator. J Cardiovasc Electrophysiol 2003;14:S78-S81.
51. Sra J, Bhatia A, Dhala A, et al. Electroanatomically guided catheter ablation of ventricular tachycardias causing multiple defibrillator shocks. Pacing Clin Electrophysiol 2001;24:1645-1652.
52. Stevenson WG, Friedman PL, Sweeney MO. Catheter ablation as an adjunct to ICD therapy. Circulation 1997;96:1378-1380.
53. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 1997;96:1525-1531.
54. Willems S, Borggrefe M, Shenasa M, et al. Radiofrequency catheter ablation of ventricular tachycardia following implantation of an automatic cardioverter defibrillator. Pacing Clin Electrophysiol 1993;16:1684-1692.
55. Della Bella P, De Ponti R, Uriarte JA, et al. Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings. Eur Heart J 2002;23:414-424.
56. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trial. Eur Heart J 2000;21:2071-2078.
57. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone eleven-year follow-up of a subset of patients in the Canadian implantable defibrillator study (CIDS). Circulation 2004;110:112-116.
58. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibrillator implantation narkedly nonlinear increase during 3 years of follow-up and its implications. Circulation 2004;109:1848-1853.
59. Buxton AE. The clinical use of implantable cardioverter defibrillators: Where are we now? Where should we go? Ann Intern Med 2003;138:512-514.
60. Davis HT, DeCamilla J, Bayer LW, Moss AJ. Survivorship patterns in the posthospital phase of myocardial infarction. Circulation 1979;60:1252-1258.
61. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. For the Multicenter Post-Infarction Research Group. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-258.
62. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: Structure, function, and time-dependence of risk. Circulation 1992;85(suppl I):I-2-I-10.
63. Wilber DJ, Zareba W, Hall J, et al. Time Dependence of Mortality Risk and Defibrillator Benefit After Myocardial Infarction. Circulation 2004;109:1082-1084.
64. Exner DV, Klein GJ. Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death? J Cardiovasc Electrophysiol 2003;14:574-577.
65. Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease an analysis of patients enrolled in the Multicenter Unsustained Tachycardia Trial. Circulation 2002;106:2466-2472.
66. Burns RJ, Gibbons RJ, Yi Q, et al. The relationship of left ventricular ejection fraction, end-systolic volume index and infarct size to six month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30-36.
67. Hallstrom A, Pratt CM, Greene HL, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial. JAm Coll Cardiol 1995;25:1250-1257.
68. PCD Investigator Group. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: An international multicenter study. J Am Coll Cardiol 1994;23:1521-1530.